The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly

Peng Wang, Min Zhu, Dong Zhang, Xue-Guang Guo, Shu Zhao, Xue-Lin Zhang, De-Long Wang, Chang-Ting Liu, Peng Wang, Min Zhu, Dong Zhang, Xue-Guang Guo, Shu Zhao, Xue-Lin Zhang, De-Long Wang, Chang-Ting Liu

Abstract

Objectives: Chronic obstructive pulmonary disease (COPD) and NSCLC often coexist and have poor prognoses, but studies investigating the impact of COPD on NSCLC have reported inconsistent findings. The objective of this study was to compare survival between NSCLC patients with and without COPD.

Methods: Medical records were retrospectively collected from 301 elderly patients pathologically diagnosed with NSCLC from the Chinese PLA General Hospital. Ultimately, a total of 200 patients were enrolled in the analysis. The survival rates between the COPD-NSCLC and non-COPD NSCLC were assessed using log-rank and Cox proportional hazard regression analyses.

Results: A total of 117 COPD-NSCLC and 93 non-COPD NSCLC patients were enrolled in the analysis. The median overall survival times were 108.5 months in the non-COPD group and 45.0 months in the COPD group (HR: 2.05; 95% CI, 1.36-2.97, P = 0.0004). After 118 patients underwent propensity score matching, the median overall survival times were 100.6 months in the non-COPD group and 51.9 months in the COPD group (HR: 1.59; 95% CI, 1.096-2.64, P = 0.0459). The multivariate analysis showed that presence of COPD (HR 1.619, P = 0.030), old age (HR 1.007, P < 00001), an advanced disease stage (stage Ⅲ HR 5.513, P < 0.0001; stage Ⅳ HR 11.743, P < 0.0001), the squamous cell carcinoma histological subtype (HR 3.106, P < 0.0001), the presence of a cough (HR 2.463, P = 0.001) a higher serum carcinoembryonic antigen level (HR 1.001, P = 0.023) and higher NRL (HR 2.615, P = 0.007) were independent factors that were significantly associated with poorer survival.

Conclusion: A diagnosis of COPD had significant poorer survival outcomes in NSCLC than that of patients without COPD in this elderly population.

Keywords: cancer management; cancer risk factors; lung cancer.

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Kaplan–Meier curve of overall survival showing presence versus absence of chronic obstructive pulmonary disease 105 × 73 mm (300 × 300 DPI)
Figure 2
Figure 2
Kaplan–Meier curve of overall survival showing presence versus absence of chronic obstructive pulmonary disease after propensity score matching 105 × 73 mm (600 × 600 DPI)

References

    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115‐132.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7‐30.
    1. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179‐191.
    1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347‐365.
    1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765‐773.
    1. Potton E, McCaughan F, Janes S. Chronic obstructive pulmonary disease and lung cancer. Respiratory Medicine: COPD Update. 2009;5(2):34‐37.
    1. Vagulienė N, Žemaitis M, Miliauskas S, Urbonienė D, Brigita, Sakalauskas R. Comparison of C‐reactive protein levels in patients with lung cancer and chronic obstructive pulmonary disease. Medicina (Kaunas). 2011;47(8):421‐427.
    1. Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology. 2011;16(7):1047‐1055.
    1. Lee SJ, Lee J, Park YS, et al. Impact of chronic obstructive pulmonary disease on the mortality of patients with non–small‐cell lung cancer. J Thorac Oncol. 2014;9(6):812‐817.
    1. Gullón JA, Suárez I, Medina A, Rubinos G, Fernández R, González I. Role of emphysema and airway obstruction in prognosis of lung cancer. Lung Cancer (Amsterdam, Netherlands). 2011;71(2):182‐185.
    1. Mina N, Soubani AO, Cote ML, et al. The relationship between chronic obstructive pulmonary disease and lung cancer in African American patients. Clin Lung Cancer. 2012;13(2):149‐156.
    1. Sekine Y, Yamada Y, Chiyo M, et al. Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection. Ann Thorac Surg. 2007;84(3):946‐950.
    1. Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early‐stage non‐small cell lung cancer undergoing surgical resection. Chest. 2014;145(2):346‐353.
    1. Zhu Y, Spitz MR, Lei L, et al. A single nucleotide polymorphism in the matrix metalloproteinase‐1 promoter enhances lung cancer susceptibility. Cancer Res. 2001;61(21):7825‐7829.
    1. Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet. 2002;11(5):569‐576.
    1. Pillai SG, Kong X, Edwards LD, et al. Loci identified by genome‐wide association studies influence different disease‐related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(12):1498‐1505.
    1. Bailey‐Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23‐25. Am J Hum Genet. 2004;75(3):460‐474.
    1. Gresner P, Gromadzinska J, Wasowicz W. Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer. Lung Cancer (Amsterdam, Netherlands). 2007;57(1):4124‐25.
    1. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633‐637.
    1. Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer. 2013;13(4):233‐245.
    1. Caramori G, Casolari P, Cavallesco GN, Giuffrè S, Adcock I, Papi A. Mechanisms involved in lung cancer development in COPD. Int J Biochem Cell Biol. 2011;43(7):1030‐1044.
    1. Kuo C‐H, Wu C‐Y, Lee K‐Y, et al. Chronic obstructive pulmonary disease in stage I non‐small cell lung cancer that underwent anatomic resection: the role of a recurrence promoter. COPD. 2014;11(4):407‐413.
    1. Tan L‐E, A M R, Lim C‐S. A MR, Lim CS: Association of chronic obstructive pulmonary disease and postresection lung cancer survival: a systematic review and meta‐analysis. J Investig Med. 2017;65(2):342‐352.
    1. Ueda K, Jinbo M, Li T‐S, Yagi T, Suga K, Hamano K. Computed tomography‐diagnosed emphysema, not airway obstruction, is associated with the prognostic outcome of early‐stage lung cancer. Clin Cancer Res. 2006;12(22):6730‐6736.
    1. Zhou C, Wu Y‐L, Chen G, et al. Erlotinib versus chemotherapy as first‐line treatment for patients with advanced EGFR mutation‐positive non‐small‐cell lung cancer (OPTIMAL, CTONG‐0802): a multicentre, open‐label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735‐742.
    1. Lee CK, Wu YL, Ding PN, et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR‐mutant lung cancer: a meta‐analysis. J Clin Oncol. 2015;33(17):1958‐1965.
    1. Yang J‐H, Wu Y‐L, Schuler M, et al. Afatinib versus cisplatin‐based chemotherapy for EGFR mutation‐positive lung adenocarcinoma (LUX‐Lung 3 and LUX‐Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141‐151.
    1. Solomon BJ, Mok T, Kim DW, et al. First‐line crizotinib versus chemotherapy in ALK‐positive lung cancer. N Engl J Med. 2014;371(23):2167‐2177.
    1. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non‐small‐cell lung cancer: results from a randomised, placebo‐controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527‐1537.
    1. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non‐small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1(8):847‐855.
    1. Solomon B, Varella‐Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non‐small cell lung cancer. J Thorac Oncol. 2009;4(12):1450‐1454.
    1. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first‐line therapy in patients with stage IV squamous non‐small‐cell lung cancer (SQUIRE): an open‐label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763‐774.
    1. Soria J‐C, Felip E, Cobo M, et al. Afatinib versus erlotinib as second‐line treatment of patients with advanced squamous cell carcinoma of the lung (LUX‐Lung 8): an open‐label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897‐907.
    1. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non‐small‐cell lung cancer (LUME‐Lung 1): a phase 3, double‐blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143‐155.
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous‐Cell Non‐Small‐Cell Lung Cancer. N Engl J Med. 2015;373(2):123‐135.
    1. Kvale PA. Chronic cough due to lung tumors: ACCP evidence‐based clinical practice guidelines. Chest. 2006;129(1 Suppl):147S‐153S.
    1. Harle A, Blackhall FH, Smith JA, Molassiotis A. Understanding cough and its management in lung cancer. Curr Opin Support Palliat Care. 2012;6(2):153‐162.
    1. Sakurai S, Shirai T, Akamatsu T, et al. Endobronchial lesions as a predictor of impaired cough‐related quality of life in lung cancer. Lung Cancer (Amsterdam, Netherlands). 2016;96:25‐26.
    1. Molassiotis A, Lowe M, Ellis J, et al. The experience of cough in patients diagnosed with lung cancer. Support Care Cancer. 2011;19(12):1997‐2004.
    1. Molassiotis A, Ellis J, Wagland R, et al. The Manchester cough in lung cancer scale: the development and preliminary validation of a new assessment tool. J Pain Symptom Manage. 2013;45(2):179‐190.
    1. Kawachi R, Suzuki K, Kunitoh H, Watanabe S‐I, Asamura H, Tsuchiya R .: Prognosis of lung cancer patients with high preoperative carcinoembryonic antigen (CEA) level: Are they surgical candidates. J Clin Oncol. 2004;22(14_suppl):7181.
    1. Jiang R, Wang X, Li K. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation‐specific in resectable non‐small‐cell lung cancer. Oncotarget. 2016;7(18):26823‐26836.
    1. Wei H, Su M, Lin R, Li H, Zou C. Prognostic factors analysis in EGFR mutation‐positive non‐small cell lung cancer with brain metastases treated with whole brain‐radiotherapy and EGFR‐tyrosine kinase inhibitors. Oncol Lett. 2016;11(3):2249‐2254.
    1. Han Y‐C, Yang T‐H, Kim D‐I, et al. Neutrophil to lymphocyte ratio predicts long‐term clinical outcomes in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Korean Circulation Journal. 2013;43(2):93‐99.
    1. Templeton AJ, McNamara MG, Šeruga B, et al.: Prognostic role of neutrophil‐to‐lymphocyte ratio in solid tumors: a systematic review and meta‐analysis. J Natl Cancer Inst. 2014;106(6):dju124.
    1. Furutate R, Ishii T, Motegi T, et al. The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. Intern Med. 2016;55(3):223‐229.
    1. Günay E, Sarınç Ulaşlı S, Akar O, et al. Neutrophil‐to‐lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation. 2014;37(2):374‐380.
    1. Gu X‐B, Tian T, Tian X‐J, Zhang X‐J. Prognostic significance of neutrophil‐to‐lymphocyte ratio in non‐small cell lung cancer: a meta‐analysis. Sci Rep. 2015;5:12493.
    1. Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil‐to‐lymphocyte ratio as a marker of outcomes in nivolumab‐treated patients with advanced non‐small‐cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2017;106:4124‐7.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner